Patient safety issues in CKD: Core curriculum 2015

American Journal of Kidney Diseases

Volumn 66, Issue 1, 2015, Pages 159-169

  Wagner, Lee Ann ^a   Tata, Asha L ^b   Fink, Jeffrey C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; GADOLINIUM; IODINATED CONTRAST MEDIUM; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; POTASSIUM; ANALGESIC AGENT; ANTIDIABETIC AGENT; CONTRAST MEDIUM; INSULIN; IODINE DERIVATIVE;

ANALGESIA; ANEMIA; ANTICOAGULANT THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; GLYCEMIC CONTROL; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; IRON THERAPY; NEPHROTOXICITY; PATIENT SAFETY; POLYPHARMACY; ACUTE KIDNEY FAILURE; AGED; ARRHYTHMIAS, CARDIAC; BACTERIAL INFECTIONS; CHEMICALLY INDUCED; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; DRUG INTERACTION; GLOMERULUS FILTRATION RATE; KIDNEY; MEDICATION ERROR; METABOLIC CLEARANCE RATE; METABOLISM; PATHOPHYSIOLOGY; PHARMACOKINETICS; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ACUTE KIDNEY INJURY; AGED; ANALGESICS; ANEMIA; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; ARRHYTHMIAS, CARDIAC; BACTERIAL INFECTIONS; CONTRAST MEDIA; DIABETIC NEPHROPATHIES; DRUG INTERACTIONS; GADOLINIUM; GLOMERULAR FILTRATION RATE; HEMATINICS; HUMANS; HYPERKALEMIA; HYPOGLYCEMIC AGENTS; INSULIN; IODINE COMPOUNDS; KIDNEY; MEDICATION ERRORS; METABOLIC CLEARANCE RATE; PAIN MANAGEMENT; PATIENT SAFETY; PHARMACOKINETICS; PLATELET AGGREGATION INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84937518127     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.02.343     Document Type: Article

References (33)

1. Frequently asked questions about GFR estimates. January 1, 2014. https://www.kidney.org/sites/default/files/docs/12-10-4 004-abe-faqs-aboutgfrrev1b-singleb.pdf. Accessed January 12, 2015.
2. Nyman HA, DowlingTC,Hudson JQ, PeterWLS, JoyMS, Nolin TD. Comparative evaluation of the Cockcroft-Gault equation and the Modification of Diet in Renal Disease (MDRD) Study equation for drug dosing: an opinion of the Nephrology Practice and ResearchNetwork of theAmerican College of Clinical Pharmacy. Pharmacotherapy. 2011;31(11):1130-1144.
3. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757-773.
4. Hazzan AD, Shah HH, Hong S, Sakhiya V, Wanchoo R, Fishbane S. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer. Kidney Int. 2014;86(1):34-39.
5. Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease. Iran J Kidney Dis. 2013;7(1):9-22.
6. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032.
7. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
8. Einhorn LM, Zhan M, Hsu VD, et al. Frequency of hyperkalemia and its significance in CKD. Arch Intern Med. 2009;169(12):1156-1162.
9. Espinel E, Joven J, Gil I, et al. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study. BMC Res Notes. 2013;6:306.
10. Fink JC. Chronic kidney disease: the effect of CKD therapies on serum potassium levels. Nat Rev Nephrol. 2010;6(11):633-634.
11. Korgaonkhar S, Tilea A, Gillespie BW, et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol. 2010;5(5):762-769.
12. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211-221.
13. Weir MR, Rolfe M. Potassium homeostasis and reninangiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5(3):531-548.
14. Arnouts P, Bolignano D, Nistor I, et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrol Dial Transplant. 2014;29(7):1284-1300.
15. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121-1127.
16. Davison, SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dial. 2014;27(2):188-204.
17. Nayak-Rao S. Achieving effective pain relief in patients with chronic kidney disease: a review of analgesics in renal failure. J Nephrol. 2011;24(1):35-40.
18. Phuong-Chi TP, Toscano E, Phuong-Mai TP, et al. Pain management in patients with chronic kidney disease. NDP Plus. 2009:2(2):111-118.
19. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med. 2008;36(4 suppl):S216-S223.
20. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009;4(7):1275-1283.
21. Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007;75(10):1487-1496.
22. Zuber K, Liles AM, Davis J. Medication dosing in patients with chronic kidney disease. JAAPA. 2013;26(10):19-25.
23. Basra SS, Tsai P, Lakkis NM. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome in patients with chronic kidney disease. J Am Coll Cardiol. 2011;58(22):2263-2269.
24. Dapodanno D, Angiolillo DJ.Antithrombotic therapy in patients with chronic kidney disease. Circulation. 2012;125(21):2649-2661.
25. Harder S. Renal profiles of anticoagulants. J Clin Pharmacol. 2012;52(7):964-975.
26. Lane DA, Lip GYH. Use of the CHA2DS2-VASc and HASBLED scores to aid decision making for thromboprophylaxis in non-valvular AF. Circulation. 2012;126(7):860-865.
27. Reinecke H, Engelbertz C, Schäbitz WR. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. Stroke. 2013;44(10):2935-2941.
28. Nyman U, Almén T, Jacobsson B, Aspelin P. Are intravenous injections of contrast media really less nephrotoxic than intraarterial injections? Eur Radiol. 2012;22(6):1366-1371.
29. Reddan D, Laville M, Garovic VD. Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings? J Nephrol. 2009;22(3):333-351.
30. Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation. 2010;122(23):2451-2455.
31. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) Study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115(25):3189-3196.
32. Voeltz MD, Nelson MA, McDaniel MC, Manoukian SV. The important properties of contrast media: focus on viscosity. J Invasive Cardiol. 2007;19(3):1A-9A.
33. Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H.Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69(7):661-668.